Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The secreted protein encoded by CYR61 is growth factor-inducible and promotes the adhesion of endothelial cells. Additionally we are shipping CYR61 Proteins (23) and CYR61 Kits (21) and many more products for this protein.
Showing 10 out of 188 products:
Human Polyclonal CYR61 Primary Antibody for BP, ICC - ABIN151820
Gashaw, Stiller, Böing, Kimmig, Winterhager: Premenstrual regulation of the pro-angiogenic factor CYR61 in human endometrium. in Endocrinology 2008
Show all 6 references for ABIN151820
Human Polyclonal CYR61 Primary Antibody for ICC, IF - ABIN151821
Kurozumi, Hardcastle, Thakur, Shroll, Nowicki, Otsuki, Chiocca, Kaur: Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. in Molecular therapy : the journal of the American Society of Gene Therapy 2008
Show all 4 references for ABIN151821
Human Monoclonal CYR61 Primary Antibody for EIA, IHC (p) - ABIN317510
Tong, OKelly, Xie, Mori, Lemp, McKenna, Miller, Koeffler: Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. in Oncogene 2004
Show all 3 references for ABIN317510
Human Polyclonal CYR61 Primary Antibody for IHC (fro), IHC (p) - ABIN191761
Schütze, Kunzi-Rapp, Wagemanns, Nöth, Jatzke, Jakob: Expression, purification, and functional testing of recombinant CYR61/CCN1. in Protein expression and purification 2005
Show all 2 references for ABIN191761
Human Polyclonal CYR61 Primary Antibody for IHC (fro), IHC (p) - ABIN191759
Lienau, Schell, Epari, Schütze, Jakob, Duda, Bail: CYR61 (CCN1) protein expression during fracture healing in an ovine tibial model and its relation to the mechanical fixation stability. in Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2006
Human Polyclonal CYR61 Primary Antibody for IHC, WB - ABIN223329
Mascareno, Galatioto, Rozenberg, Salciccioli, Kamran, Lazar, Liu, Pedrazzini, Siddiqui et al.: Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor ? (TGF-?1) ... in The Journal of biological chemistry 2012
Lysophosphatidic acid induced time-dependent phosphorylation of serum response factor and CRE-binding protein in in smooth muscle cells, inducing transcription of CCN1 (show CCNA2 Antibodies).
Data show that Cysteine-rich 61 (CYR61) acts as a tumor-promoting gene in pancreatic neuroendocrine tumors.
CCN1 (show CCNA2 Antibodies) is an important regulator of chondrocyte maturation during cartilage development and homeostasis.
CCN1 (show CCNA2 Antibodies) exacerbates tracheal obliterative bronchiolitis by enhancing fibroproliferation via an alphavbeta3-integrin-independent pathway.
Data show that RNA silencing of CCN family member 1 protein (CCN1 (show CCNA2 Antibodies)) inhibits retinal neovascularization (RNV) by inhibiting phosphoinositide 3-kinase (PI3K)/AKT protein signaling in mouse pup model of oxyge (show AKT1 Antibodies)n-induced retinopathy (OIR).
These findings reveal a critical role for CCN1 (show CCNA2 Antibodies) in restoring mucosal homeostasis after intestinal injury
CCN1 (show CCNA2 Antibodies) is an injury response protein that functions not only to restrict fibrosis in the liver, but also to suppress hepatocarcinogenesis by inhibiting EGFR (show EGFR Antibodies)-dependent hepatocyte compensatory proliferation
Both knockin mice expressing a mutant CCN1 (show CCNA2 Antibodies) that is unable to bind alphavbeta3/alphavbeta5 and mice with Ccn1 (show CCNA2 Antibodies) knockdown are defective in neutrophil efferocytosis, resulting in exuberant neutrophil accumulation and delayed healing.
CYR61 is upregulated in acute lung injury (ALI) and CYR61 overexpression exacerbates ALI in mice.
miR (show MLXIP Antibodies)-155 functions in tandem with CCN1 (show CCNA2 Antibodies) to modulate inflammation-induced vascular homeostasis and repair.
CCN1 (show CCNA2 Antibodies) RNAi reduced the mRNA and protein expression levels of CCN1 (show CCNA2 Antibodies), Akt (show AKT1 Antibodies) and VEGF (show VEGFA Antibodies) in the HUVECs (P<0.05). Furthermore, LY294002 reduced the mRNA and protein expression levels of CCN1 (show CCNA2 Antibodies) in the hypoxic cells (P<0.05). Therefore, CCN1 (show CCNA2 Antibodies) RNAi may offer a novel therapeutic strategy, which may aid in the treatment of pathological angiogenesis via inhibition of the PI3K (show PIK3CA Antibodies)/AktVEGF pathway
High CYR61 expression is associated with colorectal cancer.
Following the treatment of B16 cells with epirubicin and IFN-a (show IFNA6 Antibodies), CYR61 levels increased, cell growth was inhibited, and proliferating cell nuclear antigen (show PCNA Antibodies) expression decreased. Thus, CYR61 could become a therapeutic target for malignant melanoma patients with high CYR61 expression.
The present study aimed to examine the clinical relevance of NOV (show NOV Antibodies) along with CYR61 and CTGF (show CTGF Antibodies) in gastric cancer by analysing their transcript levels...the expression of NOV (show NOV Antibodies) and CYR61 was increased in gastric cancer. The elevated expression of CYR61 was associated with poorer survival. NOV (show NOV Antibodies) promoted proliferation and invasion of gastric cancer cells
Taken together, our results provide novel insights into the possible protective role of 7,8-DHF by activating Cyr61 signaling and suppressing ER stress in hypoxic HK-2 (show HK2 Antibodies) cells which have potential clinical implications for the treatment of AKI.
Data show that RNA silencing of CCN family member 1 protein (CCN1 (show CCNA2 Antibodies)) inhibits umbilical vein endothelial cell (HUVEC) proliferation under hypoxic conditions by inhibiting phosphoinositide 3-kinase (PI3K (show PIK3CA Antibodies))/AKT (show AKT1 Antibodies) protein signaling.
Studies indicate that the CYR61 CTGF (show CTGF Antibodies) NOV (show NOV Antibodies) matricellular proteins (CCN family of proteins) comprises the members CCN1 (show CCNA2 Antibodies), CCN2 (show CTGF Antibodies), CCN3 (show NOV Antibodies), CCN4 (show WISP1 Antibodies), CCN5 (show WISP2 Antibodies) and CCN6 (show WISP3 Antibodies) and have been identified in various types of cancer.
Results suggest that Cyr61 is induced by EGF (show EGF Antibodies) through the ERK (show EPHB2 Antibodies)/CREB (show CREB1 Antibodies) signal pathway and that it plays a crucial role in the migration and invasion of anaplastic thyroid cancer cells.
we demonstrate that NF2 (show NF2 Antibodies) negatively controls the invasiveness of Glioblastoma multiforme through YAP (show YAP1 Antibodies)-dependent induction of CYR61/CCN1 and miR (show MLXIP Antibodies)-296-3p.
The increased expression of CYR61 in the Day 4 corpus lutum (CL) and its transient increase by prostaglandin F2alpha in Day 6, Day 10, and Day 16 CL indicate that CYR61 may play a role in regulating angiogenesis over the life span of the CL.
Together, these results indicate that Cyr61 is an important determinant of the genetic reprogramming that occurs in mechanically challenged cells.
Mechanical regulation of the Cyr61 gene in smooth muscle cells
The secreted protein encoded by this gene is growth factor-inducible and promotes the adhesion of endothelial cells. The encoded protein interacts with several integrins and with heparan sulfate proteoglycan. This protein also plays a role in cell proliferation, differentiation, angiogenesis, apoptosis, and extracellular matrix formation.
cysteine-rich, angiogenic inducer, 61
, SMT3 suppressor of mif two 3 homolog 3
, small ubiquitin-related modifier 3
, protein CYR61-like
, CCN family member 1
, IGF-binding protein 10
, cysteine-rich angiogenic inducer 61
, insulin-like growth factor binding protein 10
, insulin-like growth factor-binding protein 10
, intermediate early
, protein CYR61
, cysteine-rich heparin-binding protein 61
, cysteine-rich, anigogenic inducer, 61
, cysteine rich protein 61
, secreted cysteine-rich protein cyr61